ArticleBone & joint open2026
Scoliosis correction in spinal muscular atrophy : the influence of genetic severity, functional level, and disease-modifying agents on postoperative outcomes.
Article in Bone & joint open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Response to Letter to the Editor Regarding "Safety and Efficacy of Magnetically Controlled Growing Rods for Early-Onset Scoliosis in the Era of Disease-Modifying Therapies: Mid-Term Results in a Homogeneous Cohort of Spinal Muscular Atrophy Type I Patients".Journal of the Pediatric Orthopaedic Society of North America · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Newer disease-modifying agents (DMA) targeting the involved survival motor neurone genes ( Methods: This retrospective cohort study evaluated patients with SMA (all types) who underwent scoliosis correction (growing rods (GR) or posterior spinal fusion (PSF)), with a minimum two-year postoperative follow-up. The primary outcome was 90-day postoperative complications by Clavien-Dindo (CD) grading. Secondary outcomes included age at surgery, SMA type, Results: In total, 87 patients (60% female), SMA types 1 (29, 33%), 2 (47, 54%), and 3 (11, 13%), were included; follow-up duration was 6.8 years (SD 4.5). PSF was performed for 62 (71%) and GR for 23 (26%) at ages 12.0 (SD 2.4) and 6.2 (SD 2.9) years, respectively. For those with DMA treatment preoperatively, postoperative complications were less severe compared with no DMA use (CD 1 to 2/CD 3 to 5: 24 (100%)/0 (0%) vs 39 (65%)/21 (35%), respectively, p = 0.005) and ICU LOS (3.0 (SD 1.2) vs 4.7 (SD 4.7) days; p = 0.048), total hospital LOS (5.0 (SD 3.4) vs 7.8 (SD 4.8) days; p < 0.001), and days intubated (0.1 (SD 0.3) vs 1.8 (SD 2.3) days; p < 0.001) were less. DMA use was associated with no deterioration in pulmonary function (p = 0.094) compared with untreated patients (p < 0.001). Conclusion: Postoperative complications were less severe (CD 1 to 2) with preoperative DMA treatment. Coupled with DMA use, pulmonary function was stabilized after scoliosis surgery at almost seven years' follow-up. Improvements in hospital LOS and days intubated postoperatively are potential benefits of preoperative DMA treatment, serving to increase confidence to offering these major orthopaedic surgeries for patients with SMA. Improvements in outcomes may also reflect advances in surgical techniques and perioperative care over the study period. Further comparative studies are warranted to better isolate the specific impacts of DMA treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.